“Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial”, J of Skin, vol. 3, p. S17, Nov. 2019, doi: 10.25251/skin.3.supp.17.